Clinicopathological analysis of primary adrenal diffuse large B-cell lymphoma: effectiveness of rituximab-containing chemotherapy including central nervous system prophylaxis

Ichikawa, Satoshi; Fukuhara, Noriko; Inoue, Ai; Katsushima, Hiroki; Ohba, Rie; Katsuoka, Yuna; Onishi, Yasushi; Yamamoto, Joji; Sasaki, Osamu; Nomura, Jun; Fukuhara, Osamu; Ishizawa, Kenichi; Ichinohasama, Ryo; Harigae, Hideo

doi:10.1186/2162-3619-2-19

Table 1 Summary of clinical findings

From: Clinicopathological analysis of primary adrenal diffuse large B-cell lymphoma: effectiveness of rituximab-containing chemotherapy including central nervous system prophylaxis

Case/Age/Sex	Initial presentation	Tumor type	Biopsy strategy	Clinical stage	PS	IPI	CT findings			PET findings		Laboratory data
Case/Age/Sex	Initial presentation	Tumor type	Biopsy strategy	Clinical stage	PS	IPI	Laterality of adrenal tumor	Maximal tumor diameter (mm) [Laterality]	Other lymphoma lesions [Maximal diameter (mm)]	SUVmax in adrenal tumor	SUVmax in adjacent LNs	LDH (IU/L)	sIL-2R(U/mL)	Serum cortisol level at baseline (μg/dL)	Serum cortisol level after ACTH stimulation* (μg/dL)
1/81/M	Incidentaloma	DLBCL	Laparoscopic adrenalectomy	IE-A	0	L-I	Unilateral	40 [L]	None	11.8	No lesions	372†	565†	13.7	24.8
2/69/M	Incidentaloma	DLBCL	Open adrenalectomy	IE-A	0	L-I	Unilateral	80 [L]	None	19.2	No lesions	376†	1374†	7.2	21.9
3/71/M	Incidentaloma	DLBCL	CT-guided needle biopsy	IIE-A	2	H-I	Bilateral	52 [L]	paraaortic LNs [17]	8.0	4.3	319†	1367†	ND	ND
								33 [R]
4/62/M	Hemiparesis	DLBCL	CT-guided needle biopsy	IV-A	2	H	Bilateral	60 [L]	Brain	24.5	No lesions	381†	ND	ND	ND
4/62/M	Hemiparesis	DLBCL	CT-guided needle biopsy	IV-A	2	H	Bilateral	67 [R]	Brain	24.5	No lesions	381†	ND	ND	ND
5/50/M	Fever, shock Cerebral infarction	DLBCL	CT-guided needle biopsy	IIE-B	4	L-I	Bilateral	57 [L]	paraaortic LNs [17]	22.4	3.5	415†	10468†	7.8	15.7‡
5/50/M	Fever, shock Cerebral infarction	DLBCL	CT-guided needle biopsy	IIE-B	4	L-I	Bilateral	58 [R]	paraaortic LNs [17]	22.4	3.5	415†	10468†	7.8	15.7‡
6/73/M	Back pain	DLBCL	CT-guided needle biopsy	IIE-A	3	H-I	Bilateral	57 [L]	paraaortic LNs [39]	26.0	14.6	345†	7303†	8.8	11.1‡
6/73/M	Back pain	DLBCL	CT-guided needle biopsy	IIE-A	3	H-I	Bilateral	22 [R]	paraaortic LNs [39]	26.0	14.6	345†	7303†	8.8	11.1‡
7/85/F	Back pain	DLBCL	CT-guided needle biopsy	IIE-A	2	H-I	Bilateral	67 [L]	paraaortic LNs [19]	21.5	8.6	529†	7777†	10.8	13.0‡
7/85/F	Back pain	DLBCL	CT-guided needle biopsy	IIE-A	2	H-I	Bilateral	39 [R]	paraaortic LNs [19]	21.5	8.6	529†	7777†	10.8	13.0‡

ACTH adrenocorticotropic hormone, CT computed tomography, DLBCL diffuse large B-cell lymphoma, F female, H high; H-I high-intermediate, IPI international prognosis index, L left, LDH serum lactate dehydrogenase, L-I low-intermediate, LNs lymph nodes, M male, ND not done, PET positron emission tomography, PS performance status, R right, sIL-2R serum soluble interleukin-2 receptor, SUVmax maximum standardized uptake value.
*Each serum cortisol level was measured at 60 min after ACTH challenge.
†The value exceeds upper limit of normal. ‡The value is below lower limit of normal.

Back to article page

ISSN: 2162-3619

Contact us

Submission enquiries: journalsubmissions@springernature.com

Experimental Hematology & Oncology

Contact us